Clinical trials: Post-menopausal Vasomotor Symptoms
Menopause, Hot Flashes
The Effect of Extended-Release Oxybutynin Chloride on Vasomotor Symptoms in Healthy Post-Menopausal Women
The objective of this study is to evaluate the safety and efficacy of extended-release oxybutynin chloride for the treatment of vasomotor symptoms, also known as hot flashes, in healthy naturally postmenopausal women.
- Trial name
- NCT00990886
- Testing
- Oxybutynin chloride
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Joint Discomfort, Joint Pain, Stiffness, Function
JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women
The goal of this interventional study is to evaluate whether the study product can help improve quality of life and reduce common menopause symptoms-such as joint discomfort, hot flashes and night sweats-in women aged 50-70.
- Conditions
- Joint Discomfort, Joint Pain, Stiffness, Function, Joint Pain, Hot Flashes
- Trial name
- NCT07238478
- Testing
- JDS-HF3.0
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Bonafide Health
Menopause, Hot Flashes
Randomized Evaluation of Natural Extract for Menopausal Wellness (RENEW)
This study will evaluate whether an 8-week course of a standardized herbal extract containing Shatavari and natural bio-enhancer ingredients can reduce menopausal symptoms in post-menopausal women.
- Trial name
- RENEW (NCT07834463)
- Testing
- Shatavari (Asparagus racemosus) Extract
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- India Glycols Ltd
Post-menopausal Vasomotor Symptoms
Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause
In this clinical research study, subjects will be given the study drug, ACER-801 (osanetant) or placebo (looks like the study drug but contains no active ingredients).
- Trial name
- NCT05325775
- Testing
- ACER-801 50 mg BID, ACER-801 100 mg BID, ACER-801 200 mg BID
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Acer Therapeutics Inc.
Postmenopause
Study Evaluating Estradiol/Trimegestone in Vasomotor Symptoms (VMS) in Post-Menopausal Women.
The purpose of this study is to evaluate vasomotor symptoms (VMS) control of the continuous regimen 17 b estradiol/trimegestone combination.
- Trial name
- NCT00195455
- Testing
- Trimegestone, 17b Estradiol
- Where
- 6 sites in Mexico
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Vasomotor Symptoms (VMS) Associated With Menopause
An Observational Study to Learn More About Vasomotor Symptoms Burden and Treatment Patterns in Menopausal Women Before and After Participating in OASIS Studies
This is an observational study to learn more about vasomotor symptoms (VSM) burden and treatment patterns in menopausal women before and after participating in OASIS studies.
- Trial name
- OASIS STAR (NCT06949553)
- Testing
- No study intervention
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Major Depressive Disorder, Vasomotor Symptoms
Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
This is a non-interventional study to review safety data on administration of desvenlafaxine succinate among Filipino patients with MDD and VMS per usual clinical practice within the first three years post commercial distribution.
- Trial name
- NCT01353963
- Testing
- desvenlafaxine succinate
- Where
- 3 sites in Philippines
- Volunteers
- 13 people
- Sponsor
- Pfizer
Hot Flashes, Hot Flash
Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women
The goal of this study is to evaluate the efficacy of a neurokinin 1,3 antagonist on improving vasomotor symptoms (VMS) and overall menopause symptoms in women between the ages of 40-70.
- Conditions
- Hot Flashes, Hot Flash, Hot Flushes, Menopause, Postmenopause, Hot Flushes and/or Sweats
- Trial name
- NCT07408115
- Testing
- JDS-HF3.0
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Bonafide Health
Hot Flushes
E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes)
This dose-finding study is being conducted to select the daily oral dose of estetrol (E4) for the treatment of vasomotor symptoms (VMS) in post-menopausal women.
- Trial name
- NCT02834312
- Testing
- Estetrol
- Where
- Belgium
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Donesta Bioscience
Postmenopausal Symptoms
Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy
This study is intended to establish the lowest effective dose of EstroGel® for the treatment of vasomotor symptoms associated with menopause.
- Trial name
- NCT00160173
- Testing
- Estrogel
- Where
- 109 sites in United States
- Volunteers
- 221 people
- Sponsor
- ASCEND Therapeutics
Menopause, Hot Flashes
A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms
The purpose of this study is to determine the effectiveness of BAY3427080 (NT-814), taken once a day, in the treatment of troublesome post-menopausal symptoms.
- Conditions
- Menopause, Hot Flashes, Night Waking
- Trial name
- SWITCH-1 (NCT03596762)
- Testing
- Elinzanetant (BAY3427080)
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 199 people
- Sponsor
- Bayer
Post-menopausal Vasomotor Symptoms
Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms
This is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose study in post-menopausal women with vasomotor symptoms. Single ascending doses of NT-814 will be investigated in 4 cohorts.
- Trial name
- RELENT-1 (NCT02865538)
- Testing
- BAY3427080
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- Bayer
Severe Vasomotor Symptom Associated With Menopause
Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive
To evaluate safety and efficacy of CE/BZA in real practice in Korea
- Trial name
- NCT02792504
- Where
- 20 sites in South Korea
- Volunteers
- 669 people
- Sponsor
- Pfizer
Vasomotor Symptoms, Menopause
FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms
This Phase II proof of concept study is designed to assess the safety and efficacy of FP-101 (60mg b.i.d.), an extended-release oral tablet product, compared to a matching placebo in the treatment of moderate-to-severe hot…
- Trial name
- NCT05312567
- Testing
- FP-101
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Fervent Pharmaceuticals
Menopause
A Survey Evaluating Prevalence, Severity and Associated Factors in East Asian Women With Moderate-to-severe Menopause-related Vasomotor Symptoms (MR-VMS)
The purpose of this study is to estimate the prevalence of Vasomotor Symptoms (VMS) and prevalence of moderate to severe VMS in peri-menopausal women and post-menopausal women aged 40-65 in East Asia (China, South Korea and…
- Trial name
- NCT04553029
- Testing
- No intervention
- Where
- 3 sites in China, South Korea and 1 more
- Volunteers
- 3,399 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Vasomotor Symptoms
Treatment of Vasomotor Symptoms in Korean Post Menopausal Women
Study to demonstrate that the therapeutic efficacy of Angeliq® is better than placebo in Korean postmenopausal women with hot flushes and other climacteric symptoms. Safety and tolerability of Angeliq.
- Trial name
- NCT00651599
- Testing
- Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)
- Where
- 4 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- Bayer